Drugs / VV-14305
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07404111 | Feb 2026 → Feb 2028 expected | endocrine exophthalmos | Kriya Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VV-14305 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07404111 ↗ |
| Route | Other | “VV-14305 will be administered via peribulbar injection.” NCT07404111 ↗ |